actin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
In clinical trials, refers to a drug (including a new drug, dose, combination, or route of administration) or procedure that has undergone basic laboratory testing and received approval from the U.S. Food and Drug Administration (FDA) to be tested in human subjects. A drug or procedure may be approved by the FDA for use in one disease or condition, but be considered experimental in other diseases or conditions. Also called investigational. (NCI) Experimental drug
==== pIII ==== pIII is the protein that determines the infectivity of the virion. pIII is composed of three domains (N1, N2 and CT) connected by glycine-rich linkers. The N2 domain binds to the F pilus during virion infection freeing the N1 domain which then interacts with a TolA protein on the surface of the bacterium. Insertions within this protein are usually added in position 249 (within a linker region between CT and N2), position 198 (within the N2 domain) and at the N-terminus (inserted between the N-terminal secretion sequence and the N-terminus of pIII). However, when using the BamHI site located at position 198 one must be careful of the unpaired Cysteine residue (C201) that could cause problems during phage display if one is using a non-truncated version of pIII. An advantage of using pIII rather than pVIII is that pIII allows for monovalent display when using a phagemid (plasmid derived from Ff phages) combined with a helper phage. Moreover, pIII allows for the insertion of larger protein sequences (>100 amino acids) and is more tolerant to it than pVIII. However, using pIII as the fusion partner can lead to a decrease in phage infectivity leading to problems such as selection bias caused by difference in phage growth rate or even worse, the phage's inability to infect its host. Loss of phage infectivity can be avoided by using a phagemid plasmid and a helper phage so that the resultant phage contains both wild type and fusion pIII.
I first learned charity and forgiveness from him; and in the light of it pierced even the 'liberal' darkness out of which I came, knowing more about 'Bloody Mary' than the Mother of Jesus—who was never mentioned except as an object of wicked worship by the Romanists." After his mother's death, Tolkien grew up in the Edgbaston area of Birmingham and attended King Edward's School, Birmingham, and later St Philip's School. In 1903, he won a Foundation Scholarship and returned to King Edward's.
Sources: en.wikipedia.org
=== Broken bone injuries in monkeys === In November 2023, the company was fined $9,000 due to the injuries of six monkeys between 2018 and 2022, mostly broken bones due to poor handling. After the injuries, four monkeys were euthanized.
But as season three reminds us, the punches hit harder when there's something worth fighting for." Jake Kleinman was positive towards the season for his review at, Inverse though considered it unnecessary: "Maybe The Boys was built for Trump, and without his constant presence, it feels less necessary. Maybe Marvel is less untouchable than it was a few years ago, and The Boys no longer feels like a scrappy parody punching up but more like Amazon punching down." Inkoo Kang from The Washington Post praised the show for its themes and performances and suggested: "It's a sturdily built season, but it might make you miss the show at its full strength."
4-Fluoro-7-nitrobenzofurazan (NBD-F) is a fluorogenic, amine labeling dye that is not fluorescent itself, but covalently reacts with secondary or primary amines to form a fluorescently labeled product. It and other fluorogenic benzofurans (i.e. NBD-Cl) are used for derivitization in HPLC applications. After the fluorogenic reaction, it can be detected with an excitation wavelength of 470 nm (blue) and an emission wavelength of 530 nm (green), enabling an HPLC limit of detection of 10 fmol.
Long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid with ATP to give a fatty acyl adenylate, plus inorganic pyrophosphate, which then reacts with free coenzyme A to give a fatty acyl-CoA ester and AMP. If the fatty acyl-CoA has a long chain, then the carnitine shuttle must be utilized (shown in the table below): Acyl-CoA is transferred to the hydroxyl group of carnitine by carnitine palmitoyltransferase I, located on the cytosolic faces of the outer and inner mitochondrial membranes. Acyl-carnitine is shuttled inside by a carnitine-acylcarnitine translocase, as a carnitine is shuttled outside. Acyl-carnitine is converted back to acyl-CoA by carnitine palmitoyltransferase II, located on the interior face of the inner mitochondrial membrane. The liberated carnitine is shuttled back to the cytosol, as an acyl-carnitine is shuttled into the matrix. If the fatty acyl-CoA contains a short chain, these short-chain fatty acids can simply diffuse through the inner mitochondrial membrane.
Sources: en.wikipedia.org
Ejaculation is the ejection of semen from the penis. It is usually accompanied by orgasm. A series of muscular contractions delivers semen, containing male gametes known as sperm cells or spermatozoa, from the penis. Ejaculation usually happens as the result of sexual stimulation, but it can be due to prostatic disease in rare cases. Ejaculation may occur spontaneously during sleep (known as a nocturnal emission). Anejaculation is the condition of being unable to ejaculate. Sperm are produced in the testicles and stored in the attached epididymides. During ejaculation, sperm are propelled up the vasa deferentia, two ducts that pass over and behind the bladder. Fluids are added by the seminal vesicles and the vasa deferentia turn into the ejaculatory ducts, which join the urethra inside the prostate. The prostate, as well as the bulbourethral glands, add further secretions (including pre-ejaculate), and the semen is expelled through the penis. Ejaculation has two phases: emission and ejaculation proper. The emission phase of the ejaculatory reflex is under control of the sympathetic nervous system, while the ejaculatory phase is under control of a spinal reflex at the level of the spinal nerves S2–4 via the pudendal nerve. A refractory period succeeds the ejaculation, and sexual stimulation precedes it. The ischiocavernosus muscle helps to stabilize the penis during erection by compressing the crus and slowing the return of blood through the veins. The bulbospongiosus muscle also contributes to erection along with the expulsion of urine and semen.
Another saRNA therapeutic, RAG-01, developed by Ractigen Therapeutics, is being investigated for the treatment of non-muscle invasive bladder cancer (NMIBC) and has shown promising early complete responses (CRs) in Phase I trial for BCG-unresponsive patients. saRNAs represent a significant advancement in RNA therapeutics, expanding the scope of RNA-based therapies to include gene activation in addition to gene silencing.
Turin, like the rest of Piedmont, was annexed by the French Empire in 1802. The city thus became the seat of the prefecture of Pô department until the fall of Napoleon in 1814, when the Kingdom of Piedmont-Sardinia was restored with Turin as its capital. In the following decades, the Kingdom of Piedmont-Sardinia led the struggle towards the unification of Italy. In 1861, Turin became the capital of the newly proclaimed united Kingdom of Italy, having been the political and intellectual centre of the Risorgimento movement. In 1865, the capital was moved to Florence, and then to Rome after the 1870 conquest of the Papal States. The 1871 opening of the Fréjus Tunnel made Turin an important communication node between Italy and France. The city in that period had 250,000 inhabitants. Some of the most iconic landmarks of the city, such as the Mole Antonelliana, the Egyptian Museum, the Gran Madre di Dio church and Piazza Vittorio Veneto, were built in this period. The late 19th century was also a period of rapid industrialisation, especially in the automotive sector: in 1899 Fiat was established in the city, followed by Lancia in 1906. The Universal Exposition held in Turin in 1902 is often regarded as the pinnacle of Art Nouveau design, and the city hosted the same event in 1911. By this time, Turin had grown to 430,000 inhabitants. After World War I, harsh conditions brought a wave of strikes and workers' protests. In 1920 the Lingotto Fiat factory was occupied.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.